Myelodysplastic Syndromes are oligo-clonal stem cell disorders that are associated with cytopenias in the peripheral blood. Major causes for morbidity and mortality in myelodysplastic syndromes (MDS) patients are infections mostly due to bacteria or fungi. Beside leucopenia per se in affected patients, function of white blood cells particularly that of neutrophils seems to be impaired. Here we summarize the available data on infections in MDS patients in general and particularly those treated with 5-azacitidine.
| INTRODUCTION
Myelodysplastic syndromes (MDS) are oligo-clonal diseases of the hematopoietic stem cell compartment resulting in peripheral cytopenias and a tendency of developing acute myeloid leukemia (AML).
MDS show an incidence of approximately 4/100 000/year. However, MDS are mainly a disease of the elderly with a sharp increase in incidence in the age decade above 70 years. Due to the demographic change in Western countries, it is expected that the MDS will play an increasing role for these health systems. Although anemia is the predominant cytopenia in the majority of patients, about 30%-50% of patients suffer from neutropenia of varying severity. Risk assessment was initially carried out based on the particular subtypes within the FAB classification. 1 The international prognostic scoring system (IPSS) was the first to include-besides medullary blast count and karyotype-the number of cytopenias, thereby indirectly taking the neutrophil count into consideration. 2 Finally, in 2012 the revised IPSS included the severity of neutropenia into risk stratification. 
| INFECTIONS IN MDS
Infections are a well-recognized complication in patients with MDS that contributes substantially to the morbidity and mortality in patients with MDS particularly in patients suffering from neutropenia. 8 Pomeroy and colleagues reported on 86 patients with MDS. In 66 of these patients, an infection was retrospectively identified. The most frequent sites of infection were pneumonias and skin infections that accounted for 41% of all infections, followed by urinary tract infection (25%) and bacteremia (22% The studies reported here are summarized in Table 1 .
| INFECTIOUS COMPLICATIONS DURING TREATMENT WITH AZA
Demethylating agents such as AZA are widely used in patients with high-risk MDS who are not eligible for intensive chemotherapy or allogeneic stem cell transplant. AZA has shown its superiority over best supportive care and low-dose cytarabin in those patients and is the first drug in MDS treatment that has led to an increase in survival in this setting. Microorganisms could be isolated in 17 patients with bacterial infections which were the most frequent (E. coli in six patients) followed by fungal infections (Aspergillus spp. in five patients and Candida spp. in two patients). As reported by Merkel and coworkers, FE mainly occurred during the first cycles of AZA treatment. 20 However, invasive fungal infections (IFI) seem to be rare complications in patients treated with AZA as it has recently been reported by Pomares et al. 21 In a retrospective analysis of 121 MDS and AML patients treated with AZA (total cycles administered 948), they identified four cases with proven/ probable IFI, translating into an incidence rate of proven/probable IFI of 0.21% per treatment cycle. The incidence was higher in patients with severe neutropenia (incidence rate 0.73% per treatment cycle and 4.1% per patient treated for the whole series). Finally, in this work the numbers needed to treat (NNT) with prophylaxis to prevent one case of IFI were 30 patients throughout the whole treatment course and 24 in severe neutropenic patients. Regarding side effects, they are more frequent in the groups receiving antibiotic prophylaxis as compared to placebo with most adverse events being gastrointestinal in nature. However, there was no significant difference regarding the incidence of resistant bacilli in quinolone treated patients as compared to the placebo groups. 22 However, the dose used in most of the trials was 500 mg once daily for levofloxacin and 500 mg twice daily for ciprofloxacin.
| ANTIBACTERIAL PROPHYLAXIS IN NEUTROPENIC PATIENTS AFTER CHEMOTHERAPY FOR TREATING CANCER
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| ANTIBACTERIAL PROPHYLAXIS IN PATIENTS WITH HIGH-RISK MDS TREATED WITH HMA
Only few data exist on the use of antibacterial prophylaxis in neutropenic MDS patients. In a small study including 28 patients of all In the survey by Merkel and colleagues, only 20 patients received prophylactic antibiotics. However, it was not stated whether these patients were less prone to infectious complications. 18 Due to this lack of evidence, national guidelines do not and cannot generally recommend the use of antibacterial drugs.
| GRANULOCYTIC GROWTH FACTORS IN PATIENTS WITH MDS
Several trials have investigated the role of granulocytic growth factors in patients with MDS. In most of the trials, treatment with G-CSF let to increased ANC. [42] [43] [44] [45] [46] However, none of the trials could demonstrate improvement in overall survival. Moreover, the effect of G-CSF on malignant clones remains unclear, with studies reporting preferential stimulation of, for example, monosomy seven clones while others do not. 47, 48 Due to the lack of substantial evidence for the prophylactic use of G-CSF in MDS, national guidelines do not recommend its use on a routine basis. 57 This is corroborated by multiple studies on deficits in the activation of neutrophil effector functions that show heterogeneous results, that is, affecting reactive oxygen species (ROS) production and phagocytic activity. 53 Prodan and coworkers show that phagocytosis is the more conserved effector function for combating bacterial invasion in MDS as low-risk MDS patients show no apparent functional defects. 58 Nevertheless, the oxidative burst activity is reduced in both low-and high-risk MDS patients. 52, 58 Interestingly, a correlation of cell counts and reduced functional activity has not been detected. Thus, neutrophil cell counts in MDS are apparently independent of neutrophil dysfunction as it has recently been characterized. 56 Overall, although not well defined in terms of underlying mechanisms, there are distinct alterations of neutrophil effector functions and marker expressions (ie, CD11b or CD16) in patients with MDS, clearly contributing to an impaired innate host defense against microbial pathogens and the susceptibility of patients with MDS to infections.
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| NEUTROPHIL DYSFUNCTION
| CONCLUSION
Patients with MDS and neutropenia are at increased risk for the development of infectious complications. Moreover, besides the absolute reduction in neutrophils, the impaired function might also substantially contribute to the susceptibility to infectious complications that are a major cause for morbidity and mortality. Probably due to neutrophil dysfunction, the use of hematopoietic growth factors has not been beneficial for these patients and data on antimicrobial prophylaxis are insufficient due to their small sample sizes and their nonrandomized design of most studies. 5-Azacitidine did not result in an increase in infection rate. 
| RECOMMENDATION
